Table 2.
Multivariate logistic regression analysis of TIC in patients with breast cancer
| Variable | Cardiotoxicity |
|||||
|---|---|---|---|---|---|---|
| Positive | Negative | OR | P value | |||
|
n = 32 |
n = 114 |
(95% CI) | ||||
| n | % | n | % | |||
| Age in years | 0.4478 | |||||
| <50 | 13 | 40.6 | 49 | 43.0 | 0.98 | |
| >50 | 19 | 59.4 | 65 | 57.0 | (0.92–1.04) | |
| BMI, n (%) | 0.3260 | |||||
| Underweight/normal weight | 7 | 21.9 | 18 | 15.8 | 0.73 | |
| Overweight/obesity | 25 | 78.1 | 96 | 84.2 | (0.39–1.37) | |
| Menopausal status, n (%) | 0.7729 | |||||
| Premenopausal | 14 | 43.8 | 51 | 44.7 | 1.23 | |
| Postmenopausal | 18 | 56.3 | 63 | 55.3 | (0.30–4.98) | |
| Hypertension, n (%) | 0.5013 | |||||
| No | 19 | 59.4 | 78 | 68.4 | 1.49 | |
| Yes | 13 | 40.6 | 36 | 31.6 | (0.47–4.78) | |
| Hyperlipidemia, n (%) | 0.2836 | |||||
| No | 25 | 78.1 | 91 | 79.8 | 0.450 | |
| Yes | 7 | 21.9 | 23 | 20.2 | (0.11–1.93) | |
| Diabetes, n (%) | 0.0551 | |||||
| No | 19 | 59.4 | 86 | 75.4 | 3.98 | |
| Yes | 13 | 40.6 | 28 | 24.6 | (0.97–16.29) | |
| Thyroid dysfunction, n (%) | 0.3340 | |||||
| Normal | 28 | 87.5 | 10 | 87.7 | 0.63 | |
| Abnormal | 4 | 12.5 | 14 | 12.3 | (0.25–1.61) | |
| TNM stage, n (%) | 0.3768 | |||||
| I/II | 8 | 25.0 | 52 | 45.6 | 1.45 | |
| III/IV | 24 | 75.0 | 62 | 54.4 | (0.64–3.27) | |
| Tumor site, n (%) | 0.0700 | |||||
| Unilateral | 26 | 81.3 | 107 | 93.9 | 3.68 | |
| Bilateral | 6 | 18.8 | 7 | 6.1 | (0.90–15.03) | |
| Surgery, n (%) | 0.1288 | |||||
| No | 12 | 37.5 | 33 | 28.9 | 0.54 | |
| Yes | 20 | 62.5 | 81 | 71.1 | (0.25–1.19) | |
| Estrogen receptor, n (%) | 0.7280 | |||||
| Positive | 16 | 50.0 | 66 | 57.9 | 1.36 | |
| Negative | 16 | 50.0 | 48 | 42.1 | (0.24–7.71) | |
| Progesterone receptor, n (%) | 0.7643 | |||||
| Positive | 13 | 40.6 | 56 | 49.1 | 1.26 | |
| Negative | 19 | 59.4 | 58 | 50.9 | (0.28–5.58) | |
| HER2 expression, n (%) | 0.5976 | |||||
| 2+ | 5 | 15.6 | 15 | 13.2 | 0.68 | |
| 3+ | 27 | 84.4 | 99 | 86.8 | (0.17–2.79) | |
| Trastuzumab, n (%) | 0.5011 | |||||
| Adjuvant/neoadjuvant | 19 | 59.4 | 84 | 73.7 | 0.62 | |
| Palliative | 13 | 40.6 | 30 | 26.3 | (0.16–2.47) | |
| Radiotherapy, n (%) | 0.8669 | |||||
| No | 17 | 53.1 | 63 | 55.3 | 1.09 | |
| Yes | 15 | 46.9 | 51 | 44.7 | (0.40–2.93) | |
| Endocrine therapy, n (%) | 0.7914 | |||||
| No | 15 | 46.9 | 49 | 43.0 | 1.18 | |
| Yes | 17 | 53.1 | 65 | 57.0 | (0.35–4.01) | |
| Anthracycline, n (%) | 0.4249 | |||||
| No | 22 | 68.8 | 76 | 66.7 | 0.77 | |
| Yes | 10 | 31.2 | 38 | 33.3 | (0.41–1.45) | |
| Taxane, n (%) | 0.0863 | |||||
| No | 12 | 37.5 | 48 | 42.1 | 1.72 | |
| Yes | 20 | 62.5 | 66 | 57.9 | (0.93–3.21) | |